BUSPIRONE HYDROCHLORIDE tablet Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

buspirone hydrochloride tablet

preferredpharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 10 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

ALPRAZOLAM tablet Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

alprazolam tablet

preferredpharmaceuticals inc. - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam tablets are indicated for the:  alprazolam tablets are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including alprazolam, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/ .   risk summary neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8) and clinical considerations)]. available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data).   the background risk of major birth defects and miscarriage for the indicated population is unkn

Bacterial infectious disease IVDs Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bacterial infectious disease ivds

r-biopharm pty ltd - ct353 - bacterial infectious disease ivds - ivds that are intended to be used in testing to provide information about infection with or exposure to one or a number of bacterial diseases.

Clinical chemistry-specific protein IVDs Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

clinical chemistry-specific protein ivds

r-biopharm pty ltd - ct974 - clinical chemistry-specific protein ivds - for quantitative determination of ?1-antitrypsin, secretoric iga or calprotectin in stool samples. these parameters are determined for clarification in cases of abdominal discomfort.

Viral infectious disease IVDs Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

viral infectious disease ivds

r-biopharm pty ltd - ct355 - viral infectious disease ivds - ivds to be used in testing to provide information about infection with or exposure to norovirus, adenovirus, rotavirus or astrovirus.

Clinical chemistry therapeutic drug monitoring IVDs Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

clinical chemistry therapeutic drug monitoring ivds

r-biopharm pty ltd - ct860 - clinical chemistry therapeutic drug monitoring ivds - intended to be used in monitoring of therapeutic drug levels in a clinical specimen